Big Data in Genomics

The Data Explosion in Genomics

The cost of sequencing a complete human genome has dropped faster than almost any technology in history. The Human Genome Project, completed in 2003, cost approximately 2.7 billion dollars and took 13 years. By 2014, the cost had fallen below 1,000 dollars, and current sequencing platforms can produce a complete human genome for less than 200 dollars in under 24 hours. This dramatic reduction in cost has shifted the bottleneck in genomics from data generation to data analysis and storage.

The raw output from a modern sequencing instrument is enormous. An Illumina NovaSeq X Plus, one of the most widely used high-throughput sequencers, can produce up to 16 terabytes of raw data in a single run lasting approximately two days. Even after compression and initial processing, the output for each sequenced genome remains in the range of 30 to 100 gigabytes depending on the coverage depth and analysis performed.

Beyond whole genome sequencing, other genomics technologies generate their own large datasets. RNA sequencing, which measures gene expression levels, produces smaller datasets per sample but is often applied to thousands of samples in a single study. Single-cell sequencing, which profiles individual cells rather than tissue averages, multiplies the data volume by the number of cells analyzed, which can reach millions in a single experiment. Spatial transcriptomics adds geographic coordinates within tissue sections, further increasing data complexity.

The global volume of genomic data is growing at an estimated rate of 2 to 40 exabytes per year, depending on which data types are included. The Sequence Read Archive at the National Center for Biotechnology Information, the world's largest public repository of raw sequencing data, holds more than 50 petabytes and continues to grow rapidly. By some estimates, genomics will generate more data than astronomy, YouTube, and Twitter combined within the next decade.

Computing Infrastructure for Genomics

Processing genomic data requires significant computational resources. Aligning billions of short DNA reads to a reference genome is computationally intensive, with a single whole genome taking several hours on a modern multi-core workstation. Variant calling, which identifies differences between the sequenced genome and the reference, adds additional processing time. A full analysis pipeline from raw sequencing data to annotated variants can require 24 to 48 hours of computation per genome on a standard workstation.

Cloud computing has transformed how genomics research groups access computing resources. Rather than purchasing and maintaining expensive computing clusters, researchers can launch virtual machines on Amazon Web Services, Google Cloud Platform, or Microsoft Azure, run their analyses, and release the resources when finished. This on-demand model is particularly valuable for genomics because workloads are highly variable, with intense computation during analysis periods followed by quiet periods during sample collection and sequencing.

Distributed processing frameworks have been adapted for genomics workloads. The Genome Analysis Toolkit, or GATK, developed by the Broad Institute, is the gold standard for variant calling and now supports distributed execution on Apache Spark through its GATK4 release. The ADAM project provides a set of genomics data structures and processing tools built natively on Spark, enabling distributed analysis of large genomic datasets using the same framework used for general-purpose big data processing.

Specialized genomics platforms have emerged to simplify large-scale analyses. Terra, developed by the Broad Institute and Verily, provides a cloud-based platform for genomic analysis that integrates data management, workflow execution, and interactive analysis in a single environment. DNAnexus offers a similar platform used by several national genomics programs. These platforms abstract away the complexity of distributed computing, allowing biologists to run sophisticated analyses without deep expertise in computer science.

Population-Scale Genomics Studies

The UK Biobank is one of the most ambitious population-scale genomics projects ever undertaken. It has collected genetic data, health records, lifestyle information, and physical measurements from more than 500,000 participants across the United Kingdom. The full dataset, including whole genome sequences for all participants, represents several petabytes of data. Researchers worldwide use this resource to identify genetic variants associated with diseases, drug responses, and other traits, with more than 30,000 researchers registered to access the data.

The All of Us Research Program, led by the National Institutes of Health in the United States, aims to collect health data from one million or more participants across the country, with a particular focus on including populations that have been historically underrepresented in biomedical research. The program collects whole genome sequences along with electronic health records, surveys, wearable device data, and environmental exposure measurements, creating a uniquely comprehensive dataset for studying the interplay between genetics, environment, and health.

National genomics initiatives are underway in dozens of countries. Genomics England has sequenced more than 100,000 whole genomes from patients with rare diseases and cancer, leading to new diagnoses for approximately 25 percent of participants. The Estonian Biobank contains genetic data from more than 200,000 participants, representing roughly 20 percent of the adult population. These national programs are generating datasets that, when combined, have the potential to reveal genetic insights that no single study could achieve alone.

Key Analysis Challenges

Variant interpretation is one of the central challenges in genomics big data. A typical human genome contains approximately 4 to 5 million positions where the individual differs from the reference genome. The overwhelming majority of these variants are benign, and identifying the handful that actually contribute to disease risk requires integrating evidence from multiple sources, including population frequency databases, protein structure predictions, evolutionary conservation scores, and functional experimental data. Machine learning models trained on known pathogenic and benign variants are increasingly used to prioritize variants for clinical interpretation.

Data integration across studies presents significant technical challenges. Different sequencing platforms, alignment algorithms, and variant calling pipelines can produce systematically different results from the same DNA sample. Batch effects, where technical differences between processing runs introduce artificial patterns in the data, must be carefully detected and corrected before data from different sources can be meaningfully combined. Harmonization efforts like the Global Alliance for Genomics and Health develop standards and tools to facilitate data sharing across institutions and countries.

Storage and data management costs are substantial. A single whole genome sequence in compressed format requires approximately 30 to 50 gigabytes of storage. For a biobank with 500,000 participants, this translates to 15 to 25 petabytes of genomic data alone, before accounting for associated clinical and phenotypic data. Storage costs have declined significantly with cloud pricing, but they remain a major budget item for large genomics programs. Tiered storage strategies that keep frequently accessed data on fast storage while moving archival data to cheaper cold storage help manage costs.

Privacy and consent are paramount concerns because genomic data is inherently identifying. Even when names and other identifiers are removed, a genome sequence can potentially be linked back to an individual through comparison with publicly available genetic databases or through identification of rare variants shared among family members. Regulatory frameworks like GDPR in Europe and HIPAA in the United States impose strict requirements on how genomic data is stored, accessed, and shared. Federated analysis approaches, where computations are sent to the data rather than moving data to a central location, offer one path toward enabling large-scale research while maintaining participant privacy.

The Future of Genomics Data

Long-read sequencing technologies from companies like Oxford Nanopore Technologies and Pacific Biosciences are generating new types of genomic data that complement short-read approaches. Long reads span thousands to millions of bases, making it possible to resolve complex structural variants, repetitive regions, and full-length transcript isoforms that are invisible to short-read sequencing. These technologies produce different data formats and require different analysis algorithms, adding further diversity to the genomics data landscape.

Multi-omics approaches combine genomic data with data from other molecular layers, including transcriptomics, proteomics, metabolomics, and epigenomics. Integrating these different data types provides a more complete picture of biological systems but multiplies both the data volume and the analytical complexity. Developing computational methods that can jointly analyze data across multiple omics layers at population scale is an active area of research that will become increasingly important as multi-omics datasets grow.

Clinical genomics is moving toward real-time analysis and interpretation. In neonatal intensive care units, rapid whole genome sequencing is being used to diagnose critically ill infants with suspected genetic conditions. The entire process, from blood draw to diagnosis, can now be completed in under 24 hours in some centers. As sequencing costs continue to decline and analysis pipelines become more automated, genomic data will increasingly be generated and analyzed in clinical settings rather than research laboratories alone.